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Introduction 
 
The use of any medication should be based on the clinical evidence of safety and efficacy. To 
know whether cannabis should be used medicinally, we need to know whether cannabis is a 
safe and effective treatment for particular conditions, whether it is associated with significant 
adverse effects, and how it compares to other treatments for those specified conditions. 
There are a number of different pharmaceutical cannabis products as well as crude cannabis 
which can also be administered in a range of ways. However, at present, the evidence on the 
medicinal uses of most cannabis products is incomplete. 
 
In  addition  to  the  question  of  therapeutic  effectiveness,  using  cannabis  for  medicinal 
purposes raises legal, regulatory, and other practical issues. If the evidence does support 
medicinal use of cannabis, enabling patient access raises complex issues of supply and its 
organisation within the usual processes of the healthcare system, as well as issues of legally 
distinguishing medicinal from non-medicinal usage. 
 
While these questions and issues continue to raise debate, in Australia there are currently 
people using illicit  cannabis  for  medicinal  purposes.  Potentially this  means  possibly 
seriously  ill patients are being exposed to the risks associated with engaging with an illicit 
market, including arrest and prosecution, and the resultant stress and worry. Some argue that 
patients are being blocked from accessing a product which could be beneficial, by the legal 
status which is actually aimed at prohibiting non-medicinal, rather than medicinal use. They 
believe this is itself problematic. 
 
Yet, despite continued media and government attention over the last few decades, the 
current state of the evidence, combined with the legal and regulatory difficulties, continue 
to prohibit any progress in addressing this issue. 
 
To achieve this, there is a need to disentangle medical and scientific questions from legal 
and ideological ones in considering whether and how medicinal cannabis should be used in 
Australia. This is difficult to achieve, since the range of acts and regulations that control non- 
medicinal uses of cannabis will necessarily impact on medicinal use. In this background 
paper we seek to begin disentangling these issues. Whilst the background paper includes a 
discussion of laws aimed at the control of non-medicinal cannabis use, the ANCD takes no 
view on issues of legalisation or decriminalisation of cannabis for non-medicinal purposes. 
 
The paper provides an overview of what is known about medicinal cannabis use in Australia, 
the current state of the scientific and medical evidence for its use, and problems with the 
current situation  in  Australia.  We then  explore some  current responses. Given the 
complexities of this issue we are not yet seeking to provide specific guidance on how to 
resolve  the  problems,  but   rather  to   identify  areas  that  require  further  action  or 
investigation. 
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Background 
 
Cannabis is believed to have been used for medical purposes for thousands of years. The 
earliest well-documented evidence of use has been dated to 4,000 BCE in China, and textual 
evidence indicates it was used medicinally in various locations (including Greece, China, 
India, Egypt and the Middle East) up to 4,000 years ago. Cannabis has been used to treat many 
conditions, including pain, anxiety, gout, burns, dandruff, jaundice, depression, insomnia, 
appetite loss, and asthma, amongst others (Russo 2004). 
 
In the twentieth century, medicinal use of cannabis decreased, partly due to the increasing 
availability and use of opiates and synthetic drugs (Grinspoon and Bakalar 1995). Concerns 
over non-medicinal drug use led to a number of international agreements, which were 
based on the principle that drugs should only be used for medical or scientific purposes, and 
introduced controls on cannabis as well as other drugs. In Australia, restrictions were placed 
on the use, sale and possession of cannabis. Its importation was banned in 1926 by the 
Commonwealth, and State and Territory legislation was introduced from the 1920s (Griffith 
and Jenkin 1994). 
 
Australia has ratified a number of international instruments to which it has obligations, 
including the Single Convention on Narcotic Drugs 1961, the United Nations Convention on 
Psychotropic Substances 1972, and the Convention Against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances 1988. These do not prevent signatories from making cannabis 
(and other drugs) available for medical and scientific purposes (Working Party on the Use of 
Cannabis for Medical Purposes 2000). But they do have implications for how medicinal 
cannabis could be supplied and who may cultivate it, and have had an impact on domestic 
drug laws prohibiting cultivation, supply, possession, and use. 
 
Federally, cannabis and tetrahydrocannabinols are currently listed under schedule 9 of the 
Standard  for  the  Uniform  Scheduling  of  Medicines  and  Poisons  (SUSMP).  Schedule  9 
contains prohibited substances, such that this listing means the use of cannabis and 
tetrahydrocannabinols “should be prohibited by law except when required for medical or 
scientific research, or for analytical, teaching or training purposes with approval of 
Commonwealth and/or State or Territory Health Authorities” (Commonwealth of Australia 
2013). This general restriction does not present a barrier to the medicinal use of 
pharmaceutical products containing cannabinoids if they obtain registration via the 
Therapeutic Goods Administration and are rescheduled.1  In November 2012, Sativex, an 
 
 
1 
Nabilone and dronabinol (synthetic cannabinoids usually used to treat pain and wasting associated with HIV 
or chemotherapy) are included in schedule 8, which lists controlled drugs (that is, "substances which should be 
available for use but require restriction of manufacture, supply, distribution, possession and use to reduce 
abuse, misuse and physical or psychological dependence"). These cannabinoid medications have never been 
marketed in Australia and are therefore unregistered. Because of this, they were included on schedule 8 to 
enable particular patients to access them through the Special Access Scheme (SAS), a program which allows 
therapeutic goods that are not registered in Australia to be supplied to individual patients. Without specific 
listing in schedule 8, they were captured under the schedule 9 listing of cannabis and tetrahydrocannabinols, 
which had the effect of preventing SAS access. For similar reasons, nabiximols (Sativex) was included in schedule 
8 in 2010. Following the registration of Sativex in 2012, nabiximols remains on schedule 8, though other parts 
of the SUSMP were amended to reflect this change (specifically, nabiximols was moved from 
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oromucosal spray containing cannabinoids, was included in the Australian Register of 
Therapeutic Goods for the treatment of muscle spasticity related to multiple sclerosis 
(Commonwealth of Australia 2012). 
 
Over the last few decades, there have been repeated calls for access to medicinal cannabis 
in Australia, stimulated partly by case reports detailing successful treatment of individual 
patients, as well as medicinal cannabis programs in several countries. Canada’s medicinal 
cannabis program, introduced in 2001, has used a government-licensed grower and 
distributed medicinal cannabis centrally, through Health Canada, to those with medical 
evidence  of  need.  Patients (or  their  designated  carers)  have  also  been  able  to  obtain 
licenses to grow their own supply. Canada is altering its system during 2014 so that patients 
will buy supplies from licensed producers (Health Canada 2013). In the Netherlands, medicinal 
cannabis for patients with serious illnesses was made available on prescription in 2003. 
Licenses to grow medicinal cannabis are granted by the Office for Medical Cannabis, and 
growers are required to destroy any crops that are not bought by the Office. Several plant 
strains with standardised concentrations of particular cannabinoids have been developed 
(Bedrocan, Bedrobinol, Bedica and Bediol) (Mather et al. 2013). Dried herb or a standardised, 
granulated product is distributed by pharmacies and can be administered in a tea or through 
a vaporiser (NSW Government 2013). In the USA, over 20 states and the district of Columbia 
have legalised or decriminalised medicinal cannabis, although it remains illegal at the federal 
level. States have utilised a range of different schemes for exemptions from prosecution and 
for supply (NSW Government 2013). In Israel, patients may receive licenses to grow their own 
supply, and cannabis produced by other licensed growers is distributed centrally. The Czech 
Republic is also implementing a medicinal cannabis program, and some European countries 
import products from the Dutch program (Hazekamp et al. 2013). 
 
In Australia, the medical potential of cannabis was acknowledged in several Government 
reports during the 1990s, including some released by the National Drug Strategy Committee 
(1994) and the Ministerial Council on Drug Strategy (1998). A NSW Working Party on the 
Use of Cannabis for Medical Purposes investigated the issues during 1999-2001. Its final report 
recommended: 
 
 more medical research into cannabis products; 
 
 a compassionate medicinal cannabis scheme for appropriate patients, and; 
 
 a trial of exemption from prosecution for growing, possessing, or using cannabis for 
medical purposes in NSW (Working Party on the Use of Cannabis for Medical Purposes 
2000). 
 
This trial was planned in the early 2000s (Johns 2004) but did not proceed. 
 
 
 
 
 
appendix D, paragraph 3 to appendix D, paragraph 1. This was to reflect its registered status, while maintaining 
the requirement for prescription from a medical practitioner with a schedule 8 permit, generally a specialist 
practitioner) (Therapeutic Goods Administration 2003, Therapeutic Goods Administration 2010, Therapeutic 
Goods Administration 2013). 
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Committee No 4 on a subsequent   inquiry into the medicinal use of cannabis. Among its 
recommendations were to: 
 
 express the in-principle support of the NSW government for the expanded use of 
medicinal  cannabis  for  appropriate  patient  groups,  further  clinical  trials,  and 
ensuring the affordability of pharmaceutical cannabinoids (recommendation 1). 
 
  enable  medicinal  use  to  be  a  complete  defence  against  charges  of  using  or 
possessing up to 15g of cannabis; establish a register of authorised medicinal users; 
further consider supply issues; and provide education for patients and doctors 
(recommendations 2-5). (General Purpose Standing Committee No 4 2013) 
 
The NSW Government has indicated it does not support these recommendations, except for 
recommendation 1 (NSW Government 2013). 
 
 
 
Medicinal use of cannabis in Australia 
 
Despite its illicit status, some patients do use cannabis to treat a range of conditions. Very 
little is known about the population of people who use cannabis medicinally in Australia, or 
the prevalence of use. In 2001, Hall and colleagues estimated the maximum number of 
people in NSW who might have benefited from medicinal cannabis for cancer- or HIV-related 
wasting, nausea associated with chemotherapy, muscle spasticity, or chronic pain to be 
18,900 (Hall et al. 2001). However, it is not known how many people might use medicinal 
cannabis were itavailable. 
 
International studies have reported use rates of medicinal cannabis as follows (though it 
should be noted that we do not know how Australia may compare): 
 
 Surveys of patients with HIV in various US states have reported rates of cannabis use 
of between 15 and 46 per cent (Ogborne et al. 2000,  Ware et al. 2005). 
 
 Surveys of patients with HIV in Canada reported use rates of between 15 and 35 per 
cent (Ware et al. 2005, Walsh et al. 2013). 
 
 A  survey  of  chronically  ill  patients  in  Canada  found  that  32  per  cent  reported 
medicinal use of cannabis (Ware et al. 2005) 
 
 A survey of multiple sclerosis patients in Canada reported that 16 per cent had used 
cannabis medicinally (Page et al. 2003). 
 
 A survey of chronic non-cancer pain patients in Canada found that 15 per cent of 
patients had used, and 10 per cent currently used, cannabis for pain relief (Ware et 
al. 2003). 
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 A  study  of  pharmacy  dispensing  records  in  the  Netherlands  estimated  that  5-8 
 
 
people per 100,000 used medicinal cannabis (Hazekamp and Heerdink 2013). 
 
 A province-wide survey of people aged 18 and over in Ontario, Canada, found that 
2% reported using cannabis medicinally in the past year (Ogborne et al. 2000). 
 
To date one small survey of 128 people who used cannabis medicinally has been undertaken 
in Australia (Swift et al. 2005).2 Its results are largely consistent with similar surveys 
undertaken overseas (though some international research notes patients using cannabis for 
further conditions or symptoms than those listed below). The conditions or symptoms for 
which it was used by these 128 people are presented in table 1. Most respondents used 
cannabis for multiple conditions or symptoms. 
 
 
 
Table 1: Conditions/symptoms treated with cannabis 
Condition/symptom % 
Depression 56 
Chronic pain 57 
Arthritis 35 
Migraine 17 
Weight loss 26 
Persistent nausea 27 
Spinal cord injury 13 
Spasms (spasticity) 16 
Fibromyalgia 13 
Wasting 11 
ME (chronic fatigue) 13 
Neuralgia/neuropathy 12 
HIV/AIDS 8 
Multiple sclerosis 7 
Cancer 4 
Other neurological disorder 6 
Glaucoma 2 
PTSD <1 
Irritable bowel syndrome <1 
Source: Swift et al (2005) 
 
 
The survey found that use was typically long-term and regular. Many respondents had 
previously or were continuing to use cannabis non-medicinally, and some had discovered its 
therapeutic  effects  from  their  non-medicinal  use.  Others  had  tried  cannabis  at  the 
suggestion of friends or doctors. Most respondents had tried various routes of administration,  
but  reported  typically  smoking  the  cannabis.  Although  many  reported 
 
2 
The authors note two other unpublished surveys undertaken which were not available. 
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concerns with smoking, particularly with its respiratory effects, smoking was preferred due its 
quick effect, allowing self-titration of dose, as well as cost considerations. 
 
There was a high level of satisfaction among the sample with the effects of cannabis in relation 
to the condition or symptom for which it was being used. About two-thirds (62%) of 
respondents reported reducing or ceasing use of other medication after starting to use 
cannabis. This finding is consistent with international surveys, which also reveal high rates of 
patient satisfaction (Ogborne et al. 2000, Grotenhermen and Schnelle 2003, Ware et al. 
2005,  Reiman 2007,  Aggarwal et al. 2013,  Walsh et al. 2013). Many of these surveys may be 
skewed towards patients who have chosen to continue using medicinal cannabis, and of 
course these self-reported patient perceptions provide no evidence of efficacy. However, 
these surveys have been considered evidence of good toleration of medical cannabis among 
many patients. 
 
 
 
Scientific and medical evidence 
 
The evidence base for medicinal uses of cannabis is progressing, but is still very much 
incomplete. The majority of the currently available evidence concerns pharmaceutical 
preparations rather than crude cannabis. A brief overview for information purposes follows. 
 
There are over 60 cannabinoids present in cannabis plants (Ben Amar 2006). The most- 
studied at present include delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD 
does not appear to have any of the psychoactive effects associated with THC, and may 
modulate some of the effects of THC (Mather et al. 2013). 
 
In addition, there are cannabis derivatives and synthetic cannabinoids. These include 
dronabinol (synthetic THC) and nabilone (a synthetic analogue of THC). Medical cannabis 
products that have been developed include: 
 
 Marinol (dronabinol), oral tablets/capsules 
 
 Cesamet (nabilone), oral capsules 
 
 Sativex, a mouth spray containing THC and CBD (as well as some other cannabinoids 
as residue of the manufacturing process) (Hazekamp and Grotenhermen 2010) 
 
Pharmaceutical products which contain cannabinoids have received marketing approval in 
various countries. Marinol and Cesamet have been available since the 1980s in several 
countries, for nausea and vomiting associated with cancer chemotherapy; dronabinol is also 
registered for wasting or cachexia (appetite loss) associated with HIV  (Hazekamp et al. 
2013). Sativex has been approved in 24 countries at time of writing for muscle spasticity 
associated with multiple sclerosis (GW Pharmaceuticals 2014). Several other products are 
currently under investigation in clinical or early phase trials. 
 
Clinical trials have investigated medicinal cannabis products for a range of indications. These 
include pain associated with various conditions, such as cancer, HIV, multiple sclerosis, 
arthritis, and others. Systematic reviews of the evidence suggest that a number of the 
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cannabis pharmaceuticals have some efficacy for treatment of pain, particularly chronic and 
neuropathic pain (Ben Amar 2006,  Hazekamp and Grotenhermen 2010,  Borgelt et al. 2013). 
 
Trials of oral THC (i.e., nabilone and dronabinol) have shown it has efficacy for appetite 
stimulation  and  weight gain  among  patients with  HIV,  advanced  cancer,  and  anorexia. 
Several studies have confirmed its efficacy as an anti-emetic (reducing vomiting) for patients 
undergoing chemotherapy (Ben Amar 2006). 
 
Combinations of THC and CBD (including Sativex) have shown efficacy in the treatment of 
spasticity associated with multiple sclerosis. This may be partly related to its analgesic effects,  
but  also  to  its  anti-inflammatory  and  other  properties  (Hazekamp  and Grotenhermen 
2010). 
 
Cannabinoids are also thought to have some neuroprotective effects, and have been 
investigated for the treatment of glaucoma, with evidence as yet unclear (Ben Amar 2006, 
Hazekamp and Grotenhermen 2010). 
 
Studies have also been undertaken on the use of various cannabis products in treating 
obsessive-compulsive  disorder,  schizophrenia,  Tourette’s  syndrome,  spinal  cord  injuries, 
and  epilepsy  (Ben  Amar  2006,  Hazekamp  and  Grotenhermen  2010).  Cannabinoids  are 
thought to have possible antipsychotic, anticonvulsant, and anti-tumor effects.  Much of this 
research is still quite preliminary or has not yet yielded clear results. 
 
There  are  few  controlled  studies  available  on  the  medicinal  use  of  crude  or  smoked 
cannabis, though it has been investigated for treatment of pain (Borgelt et al. 2013). 
 
There is a need for more research on all of these matters, and a number of complexities and 
limitations  should  be  noted.  The  effects  of  cannabinoids  can  differ  significantly  with 
different dosages. For example, in some studies where cannabis products have shown efficacy 
for treating pain, they also appeared to increase pain at higher doses (Ben Amar 
2006). Some of the different cannabinoids appear to modulate the effects of others, and to 
interact with other medications (including other analgesics), in ways that are not yet well 
understood. Some of the effects of cannabinoids appear to increase linearly with dosage, 
while others reach a threshold (Hazekamp and Grotenhermen 2010). Cannabinoids appear 
to have highly variable effects on different individuals, which may relate to individual 
tolerance, as well as to differences in absorption. The hormone levels of individual patients 
may alter the effects of THC, and significant differences in effect by gender have been 
observed in some studies (Hazekamp and Grotenhermen 2010). There is also incomplete 
evidence surrounding the different effects of cannabinoids used via different routes of 
administration. 
 
We also lack clarity on how cannabinoids compare to other possible treatments in many 
cases. For instance, though oral THC has efficacy as an anti-emetic, it is not clear whether it 
is more efficacious than other products, particularly as the comparative research was 
undertaken several decades ago. Similarly, there is a need for more research on how 
cannabinoid analgesics compare to other analgesics, and their suitability for different patients. 
Cannabinoids may also be useful as a second-line treatment for some groups of 
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patients who do not respond to or cannot tolerate treatments with greater demonstrated 
efficacy. 
 
Cannabis products can have adverse effects, including in some cases psychotropic effects. 
Other adverse effects reported in clinical trials include dizziness, sedation/drowsiness, 
confusion, vertigo, and dry mouth (Ben Amar 2006). The acceptability of these effects needs 
to be evaluated in light of the side-effects of alternative medications for particular indications, 
as well as severity. Investigation of the neurological basis of the effects of different 
cannabinoids and the brain’s endocannabinoid system is ongoing, so that our understanding 
of the causal mechanisms involved is currently incomplete. 
 
There are also well-known adverse effects related to crude cannabis use. Acute effects can 
include anxiety and panic; impaired attention, memory or psychomotor skills; increased 
accident risk; and increased risk of psychosis among some vulnerable users. Chronic effects 
include respiratory diseases including chronic bronchitis and cancer; dependence; 
impairments of memory or learning abilities; and effects on motivation (NCPIC n.d. , Hall 
and Solowij 1998). 
 
 
 
The Australian situation 
 
Although  we  lack  data  on  the  prevalence  and  nature  of  medicinal  use  of  cannabis  in 
Australia, it appears that people are accessing or growing cannabis illicitly for medicinal use. 
This has a number of problematic consequences. By either engaging with the illicit market or 
illicitly growing their own supply, these patients are exposed to a number of risks. There are 
risks of arrest and criminal penalties, and risks to using an unregulated product of variable 
chemical  constitution  and  quality  without  medical  supervision.  In  addition,  since  many 
smoke the product, there are health risks such as respiratory damage. All these factors may 
cause additional distress for patients, many of whom may already be very ill. 
 
The Australian survey of people who used medicinal cannabis (Swift et al. 2005) reports 
that 27 per cent of respondents stated they had been arrested, cautioned or convicted for 
their medicinal cannabis use. Seventy-six per cent reported concern about the illegal status 
of cannabis and 60 per cent reported a fear of being arrested. Most respondents also reported 
issues with variability in the quality or effectiveness of their cannabis supply (Swift et al. 
2005).3 
 
 
 
 
3  
International surveys of patients using medicinal cannabis provide similar results, with some proportion of 
patients coming into contact with law enforcement and experiencing law enforcement activities that are 
aimed at controlling non-medicinal cannabis use (Ogborne et al. 2000, Aggarwal et al. 2013). These included 
searches, arrests, prosecutions and incarceration; as well as job loss, and threats of child removal and home 
eviction. Patients also reported damage to personal and family relationships and increases in depression, 
which may have been related to the illicit status cannabis use. In the USA (where the situation is further 
complicated by the inconsistent jurisdictional and federal laws) one study reported increased psychological 
distress among medicinal cannabis patients, even when psychological distress resulting from chronic illness 
itself was controlled for (Aggarwal et al. 2013). 
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Whilst this evidence is now nearly a decade old, these issues could be expected to continue 
for people using cannabis medicinally, given that legal and regulatory arrangements have 
not changed. There were 61,011 cannabis-related arrests in 2011-12, and 86% of these were 
consumer   arrests;   the   number   continues   to   increase   over   time   (Australian   Crime 
Commission 2013). The recent registration of Sativex will not affect those using for many of 
the conditions in Table 1. 
 
In the most recent National Drug Strategy Household Survey, 69 per cent of respondents 
supported legislative change to permit the medicinal use of cannabis, and 74 per cent 
supported clinical trials to investigate the medicinal uses of cannabis (Australian Institute of 
Health and Welfare 2011). This strong public support perhaps reflects the existence of much 
anecdotal evidence of its efficacy, as well as the belief that its use is primarily by terminally 
ill patients who lack other treatment options. Despite the incomplete evidence about efficacy, 
and lack of data on usage patterns, it is important to recognise that in a context where use is 
prohibited, these beliefs can have negative effects of their own. Patients who believe that a 
product exists that could help them, but that it is beyond their legitimate reach due to 
laws targeting non-medicinal use, may be caused particular distress at the lack of compassion 
this apparently signals. Some have argued that restricting the medicinal use of cannabis is 
morally problematic, on the basis that it conflicts with a general moral obligation to avoid 
inflicting unnecessary suffering (e.g., Lucas 2009). Frustration at a system which results in this 
situation may lead to decreased respect for the law. 
 
The illicit status of medicinal cannabis also impacts on our knowledge about its use, making 
it difficult to gather data on the extent of its use, and use patterns among chronically or 
terminally ill patients. This in turn hinders the correction of misinformation or information 
that lacks a good evidence-base. 
 
The ANCD does not endorse the use of medicines that have not been thoroughly evaluated 
for safety and efficacy. However, we also recognise that a situation where some patients 
use  illicit  cannabis  medicinally  is  problematic  and  may  cause  significant  problems  and 
distress for people coping with illness, and their families. We further recognise that this 
situation has not been resolved, despite several inquiries and calls to institute different 
systems, over several decades. Attempts to address this matter continue to be hindered by 
gaps in the evidence base and the difficulties of negotiating the legal and regulatory 
complexities. 
 
In the following sections, we discuss issues and challenges surrounding the various routes that 
may be taken to address them. 
 
 
 
Pharmaceutical cannabis 
 
Any medical product needs to conform to Australia’s laws and regulations governing 
therapeutic goods. Pharmaceutical cannabis products that can be assessed through the 
usual  procedures for  therapeutic goods  may  thus  provide  the  best  way  to  obtain  the 
benefits of cannabinoids for treatment. The recent approval of Sativex demonstrates that 
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this is feasible. This would mean that products are required to present evidence of safety 
and efficacy for assessment by the TGA, ensuring that available treatments have a sound 
evidence base. Products would be subject to the same quality control procedures as other 
medicines, and use could occur under medical supervision. 
 
Approval of pharmaceutical cannabis products will, however, take a significant length of time, 
including product development and testing (for the many and varied conditions for which 
it has potential uses) as well as approval processes themselves. Relying on the introduction 
of pharmaceutical products to resolve the above problems is also problematic because it 
depends on registration being sought by pharmaceutical companies. Even where the evidence 
exists this may not occur, since Australia’s comparatively small market may not offer a 
sufficient incentive to manufacturers. 
 
In addition, pharmaceutical products will be much more costly than crude cannabis. Sativex 
was reported in 2013 to cost around $500 per month or $6,000 per year (General Purpose 
Standing Committee No 4 2013). In contrast, the survey undertaken by Swift and colleagues 
(2005) reported a median weekly spend of $50 per week, or $2,600 per year, on crude 
cannabis. It is likely that some patients would continue using crude cannabis as a result, unless 
pharmaceutical products were included on the Pharmaceutical Benefits Scheme. 
 
Further, as the patient surveys reveal, many prefer smoked crude cannabis to other routes 
of administration due t o  its more rapid onset, which enables patients more easily to 
titrate their dose. As currently developed pharmaceutical preparations have a slower onset 
(Hazekamp et al. 2013), it is possible that some patients would continue use of crude cannabis 
for this reason. Oromucosal sprays recently developed or under development have been 
reported to have an absorption rate similar those of oral capsules (Mather et al. 2013), though 
patients indicate it may be more rapid, with corresponding increases in patient satisfaction 
(Hazekamp et al. 2013). 
 
 
 
Crude cannabis 
 
Arguments for enabling crude cannabis to be used medicinally can thus be made on the 
basis of the relative ease of manufacture, lower costs, and potential relative immediacy. 
However, as well as the legal and regulatory complexities this would involve, and the few 
clinical trials that have as yet been undertaken on crude cannabis, crude cannabis raises 
concerns about health risks associated with the route of administration. 
 
Although medicinal cannabis is available in a number of countries, this availability has 
occurred through other methods to those that are standard for approval and supply of 
medicines. At present, Australian laws relating to the cultivation, possession and use of 
cannabis would preclude any registration of crude cannabis via the TGA. Even if legal 
amendments that would enable legal supply and use of crude cannabis for medical purposes 
were made, it is unlikely that crude cannabis could become available through the standard 
routes for medical products in Australia. Plants cannot be patented, so it is unlikely that any 
application would be made to register cannabis plant products (Working Party on the Use of 
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Cannabis for Medical Purposes 2000).4  Even if such an application were made, there does 
not appear to currently be an evidence base available that would be sufficient to establish the 
efficacy of crude cannabis for a particular indication. In addition, plant matter may vary in 
concentration and so fail to meet quality control criteria, and any product that could be 
smoked is unlikely to meet safety criteria (Working Party on the Use of Cannabis for Medical 
Purposes 2000).5 
 
Some research on alternative routes of administration has been undertaken, though for the 
most part these other administration routes have a slower rate of absorption and so make 
dosing more difficult. The standardised, granulated plant matter supplied in the Netherlands 
is designed to be administered only as a tea or via a vaporiser. Some recent research into 
the use of vaporisers suggests comparable rapidity of onset to smoking, with fewer effects 
on the respiratory system (Fischedick et al. 2010, Van Dam and Earleywine 2010). This 
research is still in the early stages. Some have argued that smoking of cannabis may be 
acceptable in cases where a patient is terminally ill, since this would mean the long-term 
health effects of smoking are irrelevant (General Purpose Standing Committee No 4 2013) 
(although it is not clear how this might be responded to in regulatory terms). 
 
Some have voiced concerns that sanctioning of medicinal cannabis could lead to increases in 
non-medicinal use, and undermine attempts to reduce non-medicinal demand, or that 
medicinal cannabis could be diverted to the illicit market (General Purpose Standing 
Committee No 4 2013). Current evidence suggests that the introduction of medicinal cannabis 
programs has no effect on non-medicinal use, though there is a need for further research and 
systematic appraisal of these programs (Gorman and Huber 2007,  Wall et al. 
2011, Cerda et al. 2012, Harper et al. 2012,  Lynne-Landsman et al. 2013). 
 
Another concern is that, should any crude formulation of cannabis become available, this 
might alter patient and clinician choices in undesirable ways, such as choosing to use cannabis 
over other available analgesics, for which there may actually be better evidence. Like other 
medicines, cannabis may come to be used beyond those uses for which there is evidence of 
efficacy (‘off-label’ use), and there is the possibility of pressure being placed on medical 
practitioners to ensure supply. Concerns have been expressed over apparent expansions of 
the use of medicinal cannabis in some US states, either to indications where treatment with 
cannabis is not supported by any evidence or unlikely to be of benefit, or as a result of laxity 
in supply processes (Nussbaum et al. 2011). A converse situation occurred in Canada after 
the introduction of its medicinal cannabis program, with clinicians reticent to engage with 
the program leading to poor patient uptake and continued use via the illicit market (Lucas 
2009, and see Nussbaum et al. 2011). 
 
 
 
4 
In the USA, one not-for-profit company and one for-profit company are reportedly pursuing marketing approval 
from the US regulator (the Food and Drugs Administration). If they are successful this would impact on the 
likelihood of this occurring elsewhere. 
5  
Cannabis smoke has been linked to cardiovascular disease, respiratory illnesses, and cancer, as well as 
negative effects on the immune and reproductive systems. There are concerns about the effects of cannabis 
use on mental health and cognitive function, as well as the potential to lead to dependence (Copeland et al. 
2004). 
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Arguments  for  the  availability  of  crude  cannabis  for  medicinal  purposes  are  therefore 
currently hindered by the lack of sufficient, rigorously conducted medical research. Further 
research is needed in order for this route to offer an alternate system. Research into the 
safety and efficacy of non-smokeable forms of cannabis would be particularly warranted. 
 
 
 
Supply 
 
As noted above, Australia’s obligations to international instruments do not prohibit the 
medicinal use of cannabis, but do have an impact on how it could be supplied. The 1961 
Convention  introduced  a  system  of  international  controls  on  the  cultivation  of  opium 
poppies and cannabis plants. Australia would need to establish or assign a current government 
agency for the regulation of any cannabis cultivation undertaken for medical or scientific 
purposes. Licenses would need to be granted to appropriate parties. As cannabis plants are 
not approved for sale in Australia, without legislative changes any cannabis cultivated  could  
only  be  used  for  scientific  purposes,  and  not  for  supply  outside  of  a scientific or clinical 
trial (Working Party on the Use of Cannabis for Medical Purposes 2000). 
 
To import cannabis for medicinal purposes, Australia would need to specify in advance to 
the  International  Narcotics  Control  Board  the  amount  to  be  imported  each  year,  and 
provide importers with licenses and permits. Import is likely to be more expensive than 
cultivation in Australia. State or Territory laws in the jurisdiction of import may also need to 
be amended (Working Party on the Use of Cannabis for Medical Purposes 2000). 
 
The 1988 Convention requires Australia to prevent illicit cultivation of cannabis plants, but 
licensed and permitted provision for medicinal use would not contravene the Convention. 
Exemptions  from  prosecution  for  patients  growing  their  own  cannabis  for  medicinal 
purposes are thus possible without contravening international conventions (Working Party on 
the Use of Cannabis for Medical Purposes 2000). This would require formulation of a 
legislative framework. 
 
 
 
Law enforcement options 
 
The above issues mean that any provision of crude cannabis for medical purposes is unlikely 
to occur for some time. Given the difficulties with making either pharmaceutical products or 
crude cannabis available in a timely manner, some have considered options for addressing 
the problems of the current situation in the interim. Several ways to avoid the punitive pursuit 
of those who use cannabis medicinally are suggested in available literature and by 
international examples. 
 
First, some international medicinal cannabis programs rely on registration schemes; that is, 
patients with relevant conditions are placed on a registry which exempts them from 
prosecution for cultivating, possessing or using small amounts of cannabis.6 These patients 
 
 
6 
For discussion of several variations of such schemes see General Purpose Standing Committee No 4 (2013). 
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may  then  grow  their  own  cannabis,  or  obtain  it  from  central  providers,  sellers,  or 
compassion clubs, and be confident of legal protection. Such schemes may bring with them 
difficulties from a law enforcement perspective (in addition to those of supply). They result 
in there being two classes of people to whom different laws apply; and leave open that 
some patients who are unable to grow their own plants will still access the illicit market. 
Such a system has also led to privacy concerns in Canada, as patient information may be 
disclosed to law enforcement agencies (Lucas 2009). International programs have 
experienced difficulties with registration schemes being extended to many more patients 
than are likely to benefit  medically. In addition, there would be a need to restrict access to 
those patients with indications for which treatment with cannabis is medically indicated; but 
we  currently  lack  a  thorough  evidence  base  to  identify  the  relevant  conditions.  Such 
schemes can be considered problematic if they amount to a de facto sanctioning of cannabis 
as a medicine, beyond what is mandated by the evidence base. 
 
A second option noted in some of the literature is a non-enforcement agreement, where 
law enforcement officials agree not to pursue arrests or prosecutions of people who can 
show medical evidence of a relevant condition for which they are using cannabis, though 
such use would remain formally illegal (Working Party on the Use of Cannabis for Medical 
Purposes 2000). Again, this would raise a number of  difficulties. Such agreements can be 
practically difficult to institute, and may come to be applied too broadly in some cases (e.g. to 
non-medicinal uses) and too narrowly in others. Indeed, the line between medicinal and non-
medicinal use is not always clear. Thus this option may lead to inconsistent treatment of 
people who are in similar situations. And again, this solution is problematic given that it is not 
clear which, if any, conditions could be treated with crude cannabis.  It could also be 
regarded as sanctioning  the medicinal use of cannabis beyond that which is justified by the 
evidence. 
 
A  third  option,  suggested  primarily  by  legal  cases  in  the  USA  and  discussed  in  some 
Australian literature, is the use of legislative amendments to ensure that ‘medical necessity’ is 
a clear and recognised defence against charges of possessing, using, or cultivating small 
amount of cannabis in all jurisdictions (Working Party on the Use of Cannabis for Medical 
Purposes 2000). This would not resolve all of the problems of the current situation which have 
been noted: such patients might still be prosecuted, and would still be exposed to some 
of the other risks attendant with accessing an illicit product. Nonetheless this might be 
considered as an interim step while further research is undertaken and the above options 
are further examined. 
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